Tuesday, August 10, 2010
New DNA test could allow earlier detection of colon cancer
Source: AMA Morning Rounds 8/10/2010
The New York Times (8/10, D1, Wade) reports on the front of its Science Times section, "A new generation of DNA tests for colon cancer seems likely to improve the detection both of cancers and of the precancerous polyps that precede them." The Times adds that "Exact Sciences, a company based in Madison, Wis., is developing a colon cancer test based on highly methylated DNA," and "its researchers reported last month that by testing for methylated DNA at four markers, pieces of DNA drawn from specific genes, they could detect colon tumors and polyps, distinguishing them from normal tissue with 100 percent sensitivity and with no false positives."
Tuesday, June 8, 2010
US cigarette brands expose smokers to higher levels of cancer-causing agents.
Source: AMA Morning Rounds 6/2/2010
US cigarette brands expose smokers to higher levels of cancer-causing agents.
Monday, March 29, 2010
active surveillance for large numbers of prostate cancer patients
Source: AMA Morning Rounds 3/29/2010
Major medical organization endorses active surveillance for large numbers of prostate cancer patients.
Friday, March 26, 2010
Source: AMA Morning Rounds 3/26/2010
FDA panel agrees on increased restrictions on tanning bed use.
Sunday, March 21, 2010
Higher percentage of women seeking contralateral prophylactic mastectomy, mostly unnecessary
Source: AMA Morning Rounds 3/9/2010
Higher percentage of women seeking contralateral prophylactic mastectomy.
Oral contraceptives may reduce risk of death from any cause in women.
Source: AMA Morning Rounds 3/12/2010, BMJ Press Release 3/12/2010
(4) Contraceptive pill not associated with increased long-term risk of death
(Research: Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study)
http://www.bmj.com/cgi/
Women in the UK who have ever used the oral contraceptive pill are less likely to die from any cause, including all cancers and heart disease, compared with never users, according to research published on bmj.com today.
The results show a slightly higher risk in women under 45 years old who are current or recent users of the pill. The authors stress that the effects in younger women disappear after about 10 years. Furthermore, the benefits in older women outweigh the smaller excess risks among younger women.
The study continues to find a higher rate of violent or accidental death among oral contraceptive users compared with never users. The authors are unable to explain this persistent finding.
In May 1968, the Royal College of General Practitioners' (RCGP) began the RCGP Oral Contraception Study, one of the world’s largest continuing investigations into the health effects of oral contraceptives.
Early reports from the RCGP study suggested an increased risk of death among oral contraceptive users, mainly due to an excess of strokes or other vascular problems among older women or those who smoked. Although a later report suggested that these effects disappear once the pill is stopped, at the time there were relatively few cases of different types of cancer.
These latest results, led by Professor Philip Hannaford from the University of Aberdeen, relate to the 46,000 recruited women, followed for up to nearly 40 years, creating more than a million woman-years of observation.
The results show that in the longer term, women who used oral contraception had a significantly lower rate of death from any cause, including heart disease and all cancers (notably bowel, uterine body and ovarian cancers) compared with never users.
This equates to 52 fewer deaths per 100,000 woman-years.
Slightly higher rates were found among younger women who had used oral contraception, with 20 more deaths per 100,000 among those younger than 30, and four more deaths per 100,000 among 30-39 year olds.
But by the age of 50, the benefits outweighed these modest risks, with 14 fewer deaths per 100,000 among 40-49 year olds; 86 fewer deaths per 100,000 for 50-59 year olds; 122 fewer deaths per 100,000 for 60-69 year olds; and 308 fewer deaths per 100,000 for 70+ year olds.
Hannaford says: "Many women, especially those who used the first generation of oral contraceptives many years ago, are likely to be reassured by our results. However, our findings might not reflect the experience of women using oral contraceptives today, if currently available preparations have a different risk than earlier products."
The authors conclude that their results, derived from a relatively healthy UK study group, show that "oral contraception is not significantly associated with an increased long-term risk of death . . . indeed a net benefit was apparent." However, they point out that "the balance of risks and benefits may vary globally, depending upon patterns of oral contraception usage and background risk of disease."
Contact:
Philip Hannaford, Centre of Academic Primary Care, University of Aberdeen, Scotland
Email p.hannaford@abdn.ac.uk
Oral contraceptives may reduce risk of death from any cause in women.
Spending on cancer care more than doubled since 1990.
Source: AMA Morning Rounds 3/17/2010
Spending on cancer care more than doubled since 1990.
Tuesday, February 23, 2010
Aspirin associated with decreased risk for breast cancer recurrence and death
Aspirin associated with decreased risk for breast cancer recurrence and death
Women with breast cancer who take aspirin after their diagnosis may be less likely to experience recurrence or die of the disease, a new study reports.Researchers used data from the Nurses’ Health Study to perform a prospective observational study of aspirin use in 4,164 women diagnosed with stage I, II, or III breast cancer between 1976 and 2002. Patients were observed until June 2006 or until death. The study’s main outcome measure was risk for death from breast cancer, according to number of days that aspirin was taken per week. Aspirin use was first assessed 12 months after cancer diagnosis because it is contraindicated during chemotherapy. The study results were published online Feb. 16 by the Journal of Clinical Oncology.
During follow-up, 341 women died of breast cancer. The adjusted relative risks (RRs) for breast cancer death with one, two to five, and six to seven days of aspirin use per week versus no use were 1.07 (95% CI, 0.70 to 1.63), 0.29 (CI, 0.16 to 0.52) and 0.36 (CI, 0.24 to 0.54), respectively. The association was not affected by adjustment for stage, menopausal status, body mass index, or estrogen-receptor status. The adjusted RRs for recurrence were 0.91 (CI, 0.62 to 1.33), 0.40 (CI, 0.24 to 0.65), and 0.57 (CI, 0.39 to 0.82) for the same aspirin use categories compared with no use.
The study was limited because some data were obtained by self-report and because the authors did not have information on aspirin dose, among other factors. However, the authors concluded that aspirin may have a beneficial effect on survival after a breast cancer diagnosis. They called for additional studies on aspirin’s mechanism of action in this population, including a possible randomized trial.
Wednesday, January 6, 2010
Radiation overexposure from CT scans may be more widespread than previously estimated
Source: AMA Morning Rounds 12/15/09
Radiation overexposure from CT scans may be more widespread than previously estimated.
FDA investigates 300 radiation overdoses from CT scans.
Source: AMA Morning Rounds 12/16/09
FDA investigates 300 radiation overdoses from CT scans.
New, Higher Cancer Risk Estimates for CR Scans
Source: ACP Internist Weekly 12/21/09
New estimates on cancer risk of CT scans
Two new studies warn of the cancer risk posed by CT scans and suggest some risk-reduction strategies.A retrospective cross-sectional study calculated the radiation doses delivered by computed tomography (CT) scans performed at four different California hospitals. Doses ranged from 2 millisieverts (mSv) for a routine head CT to 31 mSv for a multiphase abdomen and pelvis scan. Many of the scans provided more radiation than is usually assumed to be the case; the median dose for a routine abdomen and pelvis scan was 66% higher than the expected 8 to 10 mSv. Even within each type of study, the effective dose varied significantly within and among the hospitals. There was a mean 13-fold variation between the highest and lowest doses for each procedure.
Extrapolating from these data, researchers calculated cancer risks, such that 1 in 270 women who underwent CT coronary angiography at age 40 would develop cancer from the scan. Risks were lower for men than women, and higher for younger than older patients (20-year-olds faced double the risk, 60-year-olds only half). The study was published in the Dec. 14/28 Archives of Internal Medicine.
Another study in the same issue used risk models to calculate how many cancers could eventually be attributed to CTs based on current scanning rates. Overall, they estimated that 29,000 future cancers could be caused by CT scans performed in the U.S. in 2007. Scans of the abdomen and pelvis contributed the most to the tally, and one-third of the cancers would be due to scans performed on patients between the ages of 35 and 54.
The authors of the studies and an accompanying editorial offered a number of solutions to this problem, including standardized protocols (such as have been applied to mammography), fewer multiple series examinations, dose reduction and registration, and greater use of American College of Radiology accreditation and criteria. The experts also called for a reduction in the number of inappropriate and unnecessary CT scans.
Sunday, December 6, 2009
Study shows no link between increased cell phone use, brain cancer incidence.
Source: AMA Morning Rounds 12/4/09
Study shows no link between increased cell phone use, brain cancer incidence.
Sunday, November 29, 2009
Keeping cholesterol in check may reduce prostate cancer risk, studies suggest.
Source: AMA Morning Rounds 11/4/09
Keeping cholesterol in check may reduce prostate cancer risk, studies suggest.
The AP (11/4, Marchione) reports, "Men may protect more than their hearts if they keep cholesterol in line: Their chances of getting aggressive prostate cancer may be lower." Scientists at two institutions detailed the research that led them to that conclusion in Cancer Epidemiology Biomarkers & Prevention. Even though the papers "are not definitive and have some weaknesses," they do "fit with plenty of other science suggesting that limiting fats in the bloodstream can lessen cancer risk."
HealthDay (11/3, Edelson) reported that NCI investigators reviewed "data from a study that has followed more than 29,000 Finnish men for 18 years," finding that "cholesterol levels below the generally recommended 200 milligrams per deciliter were associated with an 18 percent higher overall risk of cancer."
On Mammography — More Agreement Than Disagreement
Published at www.nejm.org November 25, 2009 (10.1056/NEJMp0911288)
On Mammography — More Agreement Than Disagreement
Ann H. Partridge, M.D., M.P.H., and Eric P. Winer, M.D.
Friday, October 30, 2009
Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors
Source: JAMA. 2009;302(16):1757-1764.
Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors
A Randomized Controlled Trial
Albertus G. Siebers, MSc; Paul J. J. M. Klinkhamer, MD; Johanna M. M. Grefte, MD, PhD; Leon F. A. G. Massuger, MD, PhD; Judith E. M. Vedder; Angelique Beijers-Broos; Johan Bulten, MD, PhD; Marc Arbyn, MD, MSc, DrTMH
Context Liquid-based cytology has been developed as an alternative for conventional cervical cytology. Despite numerous studies and systematic reviews, controversy remains about its diagnostic accuracy.
Objective To assess the performance of liquid-based cytology compared with conventional cytology in terms of detection of histologically confirmed cervical intraepithelial neoplasia (CIN).
Design, Setting, and Participants Cluster randomized controlled trial involving 89 784 women aged 30 to 60 years participating in the Dutch cervical screening program at 246 family practices. One hundred twenty-two practices were assigned to use liquid-based cytology and screened 49 222 patients and 124 practices were assigned to use the conventional Papanicolaou (Pap) test and screened 40 562 patients between April 2004 and July 1, 2006. Patients were followed up for 18 months through January 31, 2008.
Intervention Screening for CIN using liquid-based cytology or conventional papanicolaou (Pap) test and the blinded review of all follow-up of screen-positive women (blinded to the type of cytology and the initial result).
Main Outcome Measures Intention-to-treat and per-protocol analysis of the detection rates of and positive predictive values for histologically verified CIN in both cytology systems. Outcomes are presented as crude and adjusted rate ratios (adjustment for age, urbanization, study site, and period).
Results The adjusted detection rate ratios for CIN grade 1+ was 1.01 (95% confidence interval [CI], 0.85-1.19); for CIN grade 2+, 1.00 (95% CI, 0.84-1.20); for CIN grade 3+, 1.05 (95% CI, 0.86-1.29); and for carcinoma, 1.69 (95% CI, 0.96-2.99). The adjusted positive predictive value (PPV) ratios, considered at several cytological cutoffs and for various outcomes of CIN did not differ significantly from unity.
Conclusion This study indicates that liquid-based cytology does not perform better than conventional Pap tests in terms of relative sensitivity and PPV for detection of cervical cancer precursors.
Trial Registration trialregister.nl Identifier: NTR1032
Author Affiliations: Departments of Pathology (Mr Siebers, Drs Grefte and Bulten, and Ms Vedder) and Obstetrics and Gynaecology (Dr Massuger), Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; Laboratory of Pathology, PAMM Laboratories, Eindhoven, the Netherlands (Dr Klinkhamer and Ms Beijers-Broos); and Scientific Institute of Public Health, Brussels, Belgium (Dr Arbyn).
Wednesday, May 13, 2009
Cancer Patients Challenge the Patenting of a Gene
http://www.nytimes.com/2009/05/13/health/13patent.html?em
Cancer Patients Challenge the Patenting of a Gene
When Genae Girard received a diagnosis of breast cancer in 2006, she knew she would be facing medical challenges and high expenses. But she did not expect to run into patent problems.
Ms. Girard took a genetic test to see if her genes also put her at increased risk for ovarian cancer, which might require the removal of her ovaries. The test came back positive, so she wanted a second opinion from another test. But there can be no second opinion. A decision by the government more than 10 years ago allowed a single company, Myriad Genetics, to own the patent on two genes that are closely associated with increased risk for breast cancer and ovarian cancer, and on the testing that measures that risk.
On Tuesday, Ms. Girard, 39, who lives in the Austin, Tex., area, filed a lawsuit against Myriad and the Patent Office, challenging the decision to grant a patent on a gene to Myriad and companies like it. She was joined by four other cancer patients, by professional organizations of pathologists with more than 100,000 members and by several individual pathologists and genetic researchers.
The lawsuit, believed to be the first of its kind, was organized by the American Civil Liberties Union and filed in federal court in New York. It blends patent law, medical science, breast cancer activism and an unusual civil liberties argument in ways that could make it a landmark case.
Companies like Myriad, based in Salt Lake City, have argued that the patent system promotes innovation by giving companies the temporary monopoly that rewards their substantial investment in research and development.
Richard Marsh, Myriad’s general counsel, said company officials would not be able to comment on the lawsuit until they had fully reviewed the complaint.
The coalition of plaintiffs argues that gene patents actually restrict the practice of medicine and new research.
“With a sole provider, there’s mediocrity,” said Wendy K. Chung, the director of clinical genetics at Columbia University and a plaintiff in the case.
Dr. Chung and others involved with the suit do not accuse Myriad of being a poor steward of the information concerning the two genes at issue in the suit, known as BRCA1 and BRCA2, but they argue that BRCA testing would improve if market forces were allowed to work.
Harry Ostrer, director of the human genetics program at the New York University School of Medicine and a plaintiff in the case, said that many laboratories could perform the BRCA tests faster than Myriad, and for less money than the more than $3,000 the company charged.
Laboratories like his, he said, could focus on the mysteries still unsolved in gene variants. But if he tried to offer such services today, he said, he would be risking a patent infringement lawsuit from Myriad.
Christopher A. Hansen, senior national staff counsel for the civil liberties union, said the problem was with the patent office, not the company. He recalled that when he first heard that the office had granted a patent for a gene, “I said that can’t be true.”
As the A.C.L.U. explored the restrictions on competition that companies like Myriad had put in place — blocking alternatives to the patented tests, and even the practice of interpreting or comparing gene sequences that involved those genes — the restrictions started to look like not just a question of patent law, Mr. Hansen said, but of the First Amendment’s guarantee of free speech as well.
“What they have really patented,” he said, “is knowledge.”
A patent was also granted to a single company for genetic testing on long QT syndrome, which can lead to heart arrhythmias and sudden death, and to the HFE gene, linked to hereditary hemochromatosis, a condition in which iron accumulates in the blood and can cause organ damage. Doctors and scientists have complained about both patents.
On the other hand, the company that owns the patent to the gene CFTR, which has been linked to cystic fibrosis, has licensed the testing to dozens of laboratories, drawing praise from the medical world.
The decision to allow gene patents was controversial from the start; patents are normally not granted for products of nature or laws of nature. The companies successfully argued that they had done something that made the genes more than nature’s work: they had isolated and purified the DNA, and thus had patented something they had created — even though it corresponded to the sequence of an actual gene.
The argument may have convinced patent examiners, but it has long been a sore point for many scientists. “You can’t patent my DNA, any more than you can patent my right arm, or patent my blood,” said Jan A. Nowak, president of the Association for Molecular Pathology, a plaintiff in the case.
So far, however, two panels of government experts who have looked at the issue have not found significant impediments to research or medical care caused by gene patents. A 2006 report from the National Research Council found that patented biomedical research “rarely imposes a significant burden for biomedical researchers.”
That report and others, however, warn that the patent landscape “could become considerably more complex and burdensome over time.”
In the future, genetic tests are likely to involve the analysis of many genes at once, or even of a person’s full set of genes. Some 20 percent of the human genome is already included in patent claims, amounting to thousands of individual genes, says a draft report from the National Institutes of Health. The report warns that “it may be difficult for any one developer to obtain all the needed licenses” to develop the next generations of tests.
For Lisbeth Ceriani, a single mother from Newton, Mass., and a plaintiff in the case against Myriad, the biggest obstacle that gene patents present is one of cost. She has had breast cancer and a double mastectomy, but wants to have BRCA testing to determine her risk of ovarian cancer and help her decide whether to have her ovaries removed. But Myriad has refused to work with her insurance plan, Mass Health, and paying for the test herself is beyond her means.
She is reluctant to have surgery that might prove unnecessary, she said, but she also worries about her 8-year-old daughter and the inherited risk she might face. Which is why, Ms. Ceriani said, she wants to “find out if I have the mutation, so I can take the necessary steps to stay on the planet.”
“I want to be here,” she said, “to make sure she does her screening by the time she’s 30.”Monday, March 23, 2009
Meat Intake and Mortality
Meat Intake and Mortality
A Prospective Study of Over Half a Million People
Arch Intern Med. 2009;169(6):562-571.
Background High intakes of red or processed meat may increase the risk of mortality. Our objective was to determine the relations of red, white, and processed meat intakes to risk for total and cause-specific mortality.
Methods The study population included the National Institutes of Health–AARP (formerly known as the American Association of Retired Persons) Diet and Health Study cohort of half a million people aged 50 to 71 years at baseline. Meat intake was estimated from a food frequency questionnaire administered at baseline. Cox proportional hazards regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) within quintiles of meat intake. The covariates included in the models were age, education, marital status, family history of cancer (yes/no) (cancer mortality only), race, body mass index, 31-level smoking history, physical activity, energy intake, alcohol intake, vitamin supplement use, fruit consumption, vegetable consumption, and menopausal hormone therapy among women. Main outcome measures included total mortality and deaths due to cancer, cardiovascular disease, injuries and sudden deaths, and all other causes.
Results There were 47 976 male deaths and 23 276 female deaths during 10 years of follow-up. Men and women in the highest vs lowest quintile of red (HR, 1.31 [95% CI, 1.27-1.35], and HR, 1.36 [95% CI, 1.30-1.43], respectively) and processed meat (HR, 1.16 [95% CI, 1.12-1.20], and HR, 1.25 [95% CI, 1.20-1.31], respectively) intakes had elevated risks for overall mortality. Regarding cause-specific mortality, men and women had elevated risks for cancer mortality for red (HR, 1.22 [95% CI, 1.16-1.29], and HR, 1.20 [95% CI, 1.12-1.30], respectively) and processed meat (HR, 1.12 [95% CI, 1.06-1.19], and HR, 1.11 [95% CI 1.04-1.19], respectively) intakes. Furthermore, cardiovascular disease risk was elevated for men and women in the highest quintile of red (HR, 1.27 [95% CI, 1.20-1.35], and HR, 1.50 [95% CI, 1.37-1.65], respectively) and processed meat (HR, 1.09 [95% CI, 1.03-1.15], and HR, 1.38 [95% CI, 1.26-1.51], respectively) intakes. When comparing the highest with the lowest quintile of white meat intake, there was an inverse association for total mortality and cancer mortality, as well as all other deaths for both men and women.
Conclusion Red and processed meat intakes were associated with modest increases in total mortality, cancer mortality, and cardiovascular disease mortality.
Author Affiliations: Nutritional Epidemiology Branch (Drs Sinha, Cross, Leitzmann, and Schatzkin) and Biostatistics Branch (Dr Graubard), Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland.
Wednesday, March 18, 2009
Religious Belief Linked to Desire for Aggressive Treatment in Terminal Patients
Religious Belief Linked to Desire for Aggressive Treatment in Terminal Patients
Terminally ill cancer patients who drew comfort from religion were far more likely to seek aggressive, life-prolonging care in the week before they died than were less religious patients and far more likely to want doctors to do everything possible to keep them alive, a study has found.
The patients who were devout were three times as likely as less religious ones to be put on a mechanical ventilator to maintain breathing during the last week of life, and they were less likely to do any advance care planning, like signing a do-not-resuscitate order, preparing a living will or creating a health care proxy, the analysis found.
The study is to be published Wednesday in The Journal of the American Medical Association.
“People think that spiritual patients are more likely to say their lives are in God’s hands — ’Let what happens happen’ — but in fact we know they want more aggressive care,” said Holly G. Prigerson, the study’s senior author and director of the Center for Psychosocial Oncology and Palliative Care Research at the Dana-Farber Cancer Institute in Boston.
“To religious people, life is sacred and sanctified,” Dr. Prigerson said, “and there’s a sense they feel it’s their duty and obligation to stay alive as long as possible.”
Aggressive life-prolonging care comes at a cost, however, in terms of both dollars and human suffering. Medicare, the government’s health plan for the elderly, spends about one-third of its budget on people who are in the last year of life, and much of that on patients at the very end of life.
Aggressive end-of-life care can lead to a more painful process of dying, researchers have found, and greater shock and grief for the family members left behind.
The new study used both a questionnaire and interviews to assess the level of reliance on religious faith for comfort among 345 patients with advanced cancer. The patients, most of them belonging to Christian denominations, were followed until they died, about four months on average.
A vast majority of patients, religious or not, did not want heroic measures taken. Still, 11.3 percent of the most religious patients received mechanical ventilation during the last week of life, compared with only 3.6 percent of the least religious.
The most religious patients were also more likely than less religious ones to be resuscitated in the last week of life and to be treated in an intensive-care unit as they died, although those differences may have been due to chance.
“Doctors don’t always acknowledge, and I’m pretty sure patients are telling us, that God is really important in their lives,” said Dr. Gerard Silvestri, a cancer specialist at the Medical University of South Carolina in Charleston, S.C., who has studied end-of-life decision making.
A study by Dr. Silvestri in 2003 found that while cancer patients listed their oncologist’s recommendation as the most influential factor affecting their decisions about medical care, their faith in God was the second-most-influential factor, ranking higher than the recommendations of their family doctors, their spouses and children, and even information about whether treatment would cure the disease.
Prostate Cancer Test Found to Save Few Lives
Prostate Cancer Test Found to Save Few Lives
By GINA KOLATAThe PSA blood test — the screening test for prostate cancer — saves few if any lives and exposes large numbers of men to risky and unnecessary treatment, two large and rigorous studies have found.
The findings raise new questions about the rapid and widespread adoption of the test, which measures a protein released by prostate cells. It was introduced in 1987 and quickly became a routine part of preventive health care. Experts debated its value, basing their views on data that often involved statistical modeling and inferences.
Now, with the new data, cancer experts said men should carefully consider the test’s risks and benefits before deciding to be screened. Some may decide not to be screened at all.
The studies, said Dr. Otis Brawley, the chief medical officer at the American Cancer Society, are “some of the most important studies in the history of men’s health.”
For years, the cancer society has urged men to be informed before deciding to have a PSA test. “Now we actually have something to inform them with,” he said. “We’ve got numbers.”
Dr. H. Gilbert Welch, a professor of medicine at Dartmouth who studies cancer screening, also welcomed the new data. “We’ve been waiting years for this,” he said. “It’s a shame we didn’t have it 20 years ago.”
Both reports were published online on Wednesday by The New England Journal of Medicine. One involved 182,000 men in seven European countries; the other, by the National Cancer Institute, involved nearly 77,000 men at 10 medical centers in the United States.
In both, participants were randomly assigned to be screened — or not — with the PSA test, whose initials stand for prostate-specific antigen. In each study, the two groups were followed for more than a decade while researchers counted deaths from prostate cancer, asking whether screening made a difference.
The European data involved a consortium of studies with different designs. Taken together, the studies found that screening was associated with a 20 percent relative reduction in the prostate cancer death rate. But the number of lives saved was small — seven fewer prostate cancer deaths for every 10,000 men screened and followed for nine years.
The American study, which had a single design, found no reduction in deaths from prostate cancer after most of the men had been followed for 10 years. Every man has been followed for at least seven years, said Dr. Barnett Kramer, a study co-author at the National Institutes of Health. By seven years, the death rate was 13 percent lower for the unscreened group.
The European study saw no benefit of screening in the first seven years of follow-up.
The reason screening saved so few lives, cancer experts say, is that prostate cancers often grow very slowly, if at all, and most never endanger a man if left alone. But when doctors find an early-stage prostate tumor, they cannot tell with confidence whether it will be dangerous so they usually treat all early cancers as if they were life-threatening.
As a result, the majority of men, whose early-stage cancers would not harm them, suffer serious effects of cancer therapy but get no benefit. Others, with very aggressive tumors, may not be helped by screening because their cancer has spread by the time it is detected.
Prostate cancer is not the only one that is hard to stop with screening. If the European study is correct, mammography has about the same benefit as the PSA test, said Dr. Michael B. Barry, a prostate cancer researcher at Massachusetts General Hospital who wrote an editorial accompanying the papers. But prostate cancers often are less dangerous than breast cancers, so screening and subsequent therapy can result in more harm.
In the European study, 48 men were told they had prostate cancer, and needlessly treated for it, for every man whose death was prevented. With mammography, about 10 women receive a diagnosis and needless treatment for breast cancer to prevent one death.
Dr. Peter B. Bach, a physician and epidemiologist at Memorial Sloan-Kettering Cancer Center, says one way to think of the data is to suppose he has a PSA test today. It leads to a biopsy that reveals he has prostate cancer, and he is treated for it. There is a one in 50 chance that, in 2019 or later, he will be spared death from a cancer that would otherwise have killed him. And there is a 49 in 50 chance that he will have been treated unnecessarily for a cancer that was never a threat to his life or health.
Prostate cancer treatment can result in impotence and incontinence when surgery is used to destroy the prostate, and painful defecation or chronic diarrhea when the treatment is radiation.
When the American and European studies began, in the early 1990s, PSA testing was well under way in the United States, and many expected that the screening test would make the prostate cancer death rate plummet by 50 percent or more. Dr. Brawley was at the cancer institute then, though not directly involved with its prostate cancer screening study. But he saw the reactions.
Some urologists said the study was unethical, because some people would not be screened, and demanded it be shut down, he said. One group of black urologists encouraged black men not to participate because blacks have a greater risk of prostate cancer and it seemed obvious they should be screened.
Some thought that they would see fewer cancer deaths among the screened men as quickly as five years. But as the studies continued, it became clear that screening would not have a large, immediate effect — if it did, the studies would have been stopped and victory declared. Cancer researchers began turning to less rigorous sources of data, with some arguing that screening was preventing prostate cancer deaths and others arguing it was not.
In the United States, many men and their doctors have made up their minds — most men over age 50 have already been screened, and each year more than 180,000 receive a diagnosis of prostate cancer. In Europe, said Dr. Fritz H. Schröder of Erasmus University, the lead author of the European study, most men are not screened. “The mentality of Europeans is different,” he said, and screening is not so highly promoted.
The publication, of data from the two studies should change the discussion, said Dr. David Ransohoff, an internist and cancer epidemiologist at the University of North Carolina.
“This is not relying on modeling anymore,” Dr. Ransohoff said. “This is not some abstract, pointy-headed exercise. This is the real world and this is real data.”
Both studies will continue to follow the men. It remains possible that the United States study will eventually find that screening can reduce the prostate cancer death rate, researchers say, or that both studies will conclude that there is no real reduction.
In the meantime, Dr. Brawley said, “I certainly think there’s information here that’s food for thought.”
The benefits of prostate cancer screening, he said, are “modest at best and with a greater downside than any other cancer we screen for.”Web Link
Mortality Results from a Randomized Prostate-Cancer Screening Trial (The New England Journal of Medicine)
Screening and Prostate-Cancer Mortality in a Randomized European Study (The New England Journal of Medicine)
Thursday, February 5, 2009
Breast cancer risk rapidly drops after stopping hormone therapy
| Breast cancer risk rapidly drops after stopping hormone therapy
By Reuters Health February 5, 2009 |
The results of the Women's Health Initiative (WHI) trial released in 2002 linked use of estrogen plus progestin with increased breast cancer risk in postmenopausal women. Subsequently, use of this therapy in the U.S. decreased substantially accompanied by a drop in breast cancer rates. Whether the two trends were causally related, however, was unclear.
In fact, it was suspected that changes in the frequency of mammographic screening may have accounted for the apparent drop in breast cancer incidence.
To investigate, Dr. Marcia Stefanick, from Stanford University School of Medicine, California, and colleagues analyzed follow-up data from the WHI trial. Included in the postintervention phase of the trial were 7,854 women who had received conjugated equine estrogens (0.625 mg) plus medroxyprogesterone (2.5 mg) daily and 7,533 given placebo.
In the two years prior to the intervention phase of the study, fewer breast cancer diagnoses were seen in the combined hormone therapy group than in the placebo group. During the 5.6 years of intervention, however, the risk of breast cancer was 26% higher in the hormone therapy group.
After stopping hormone therapy, the risk of breast cancer fell rapidly. The annualized incidence decreased 43% within one year, and by two years it was essentially the same as in the placebo group.
Moreover, during this period, "differences in the frequency of mammography between the two groups were unchanged."
Overall, "This is very strong evidence that estrogen plus progestin causes breast cancer," Stefanick said in a statement. "You start women on hormones and within five years, their risk for breast cancer is clearly elevated. You stop the hormones and within one year, their risk is essentially back to normal. It's reasonably convincing cause-and-effect data."
Last Updated: 2009-02-04 17:00:12 -0400 (Reuters Health)
Related Reading
Current HRT use is associated with low-grade breast cancer tumors, October 22, 2008
N Engl J Med 2009;360:573-587
ABSTRACT
Background Following the release of the 2002 report of the Women's Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains controversial.
Methods We analyzed the results of the WHI randomized clinical trial — in which one study group received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily and another group received placebo — and examined temporal trends in breast-cancer diagnoses in the WHI observational-study cohort. Risk factors for breast cancer, frequency of mammography, and time-specific incidence of breast cancer were assessed in relation to combined hormone use.
Results In the clinical trial, there were fewer breast-cancer diagnoses in the group receiving estrogen plus progestin than in the placebo group in the initial 2 years of the study, but the number of diagnoses increased over the course of the 5.6-year intervention period. The elevated risk decreased rapidly after both groups stopped taking the study pills, despite a similar frequency of mammography. In the observational study, the incidence of breast cancer was initially about two times as high in the group receiving menopausal hormones as in the placebo group, but this difference in incidence decreased rapidly in about 2 years, coinciding with year-to-year reductions in combined hormone use. During this period, differences in the frequency of mammography between the two groups were unchanged.
Conclusions The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography.